Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01856426 · ClinicalTrials.gov registry record · Phase 1
Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects
A Phase 1 study of Hepatitis C, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 5
- Study locations
NCT01856426: Completed Phase 1 study of Hepatitis C, sponsored by Enanta Pharmaceuticals.
NCT01856426 is a Phase 1 study of Hepatitis C that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 28 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01856426, a Phase 1 study of Hepatitis C, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV gentotype-1 in chronically infected subjects and to further evaluate the safety profile of EDP239.
Primary Outcome
Blood will be collected for Hepatitis C viral load at Day 1.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EDP239
Study Locations (5)
Other
- Investigative Site - Frankfurt
- Investigative Site - Hamburg
Florida
- Investigative Site - Miami
Texas
- Investigative Site - San Antonio
Utah
- Investigative Site - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
What the finished NCT01856426 record still lists
NCT01856426 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01856426 lists 5 locations in 4 states (Other, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT01856426 about?
NCT01856426 is a clinical study titled "Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects". The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV gentotype-1 in chronically infected subjects and to further evaluate the safety profile of EDP239.
What is the current status of trial NCT01856426?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2013-06. Estimated completion is 2015-10.
What conditions does trial NCT01856426 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT01856426?
The interventions under investigation include: Placebo (DRUG), EDP239 (DRUG).
Who is sponsoring clinical trial NCT01856426?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01856426 being conducted?
This trial has 5 study locations across Florida, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01856426's enrollment target sits among peer trials
28 88th of 106 higher than 19 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
COMPLETED · Phase 1
-
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 1
-
Open-Label Hepatic Impairment Study
COMPLETED · Phase 1
-
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
COMPLETED · Phase 1
-
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia